How Priovant’s brepocitinib advances a long-overlooked inflammatory skin disease toward approval
Strong Phase 2 data put brepocitinib on a rare pivotal path in cutaneous sarcoidosis. Find out what this changes for clinicians and regulators.
Can Kinaset’s inhaled JAK inhibitor finally bring relief to all severe asthma patients?
Kinaset raises $103M to advance frevecitinib, a novel inhaled JAK inhibitor for severe asthma. Find out what makes this candidate different.